APA (7th ed.) Citation

K, S. V., TT, W., SN, A., & AK, B. (2022). Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: A meta-analysis on their efficacy and safety. BMC cancer, 22(1), 1139. https://doi.org/10.1186/s12885-022-10225-y

Chicago Style (17th ed.) Citation

K, Sharmni Vishnu, Win TT, Aye SN, and Basavaraj AK. "Combined Atezolizumab and Nab-paclitaxel in the Treatment of Triple Negative Breast Cancer: A Meta-analysis on Their Efficacy and Safety." BMC Cancer 22, no. 1 (2022): 1139. https://doi.org/10.1186/s12885-022-10225-y.

MLA (9th ed.) Citation

K, Sharmni Vishnu, et al. "Combined Atezolizumab and Nab-paclitaxel in the Treatment of Triple Negative Breast Cancer: A Meta-analysis on Their Efficacy and Safety." BMC Cancer, vol. 22, no. 1, 2022, p. 1139, https://doi.org/10.1186/s12885-022-10225-y.